Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Allarity Therapeutics, Inc.

NASDAQ: ALLR · Life Sciences · 8 alerts · CIK 1860657

Share price
$0.8752Close, Nov 16
Market cap
$14M
Shares outstanding
16MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Allarity Therapeutics, Inc. filings on SEC EDGAR ↗

7:51 AM ET 8-K
Loan & Debt

Allarity Therapeutics $3M Debt Financing with Streeterville Capital, LLC

Allarity Therapeutics entered into an exchange agreement with Streeterville Capital to partition $3.0 million from an existing $10.93 million promissory note. The partitioned debt was exchanged for 3,000 shares of newly designated Series B Preferred Stock, effectively reducing the company's outstanding debt balance by $3.0 million. The Series B Preferred Stock carries a 9% annual dividend and ranks senior to common stock in liquidation.

Value
$3M
Counterparty
Streeterville Capital, LLC
8:06 AM ET 10-Q
Financial Results

Allarity Therapeutics Q3 2026 Results: Net Loss of $6.2M, Loss Widens

For the nine months ended September 30, 2026, Allarity Therapeutics reported a net loss of $12.4 million, an increase from the $7.9 million loss in the prior year period, primarily driven by higher research and development costs. The company's total stockholders' equity turned to a deficit of $2.3 million as of September 30, 2026, while cash and restricted cash increased to approximately $24.1 million.

Key figure
Net loss $6.2M
8:01 AM ET 8-K
Contract Win

Allarity Therapeutics Wins Contract from unnamed European biotechnology company

Allarity Therapeutics secured its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy. The company will provide development and validation services to support a European biotechnology company's precision oncology predictive device in the U.S. market.

Counterparty
unnamed European biotechnology company
4:06 PM ET 8-K
Deal Termination

Allarity Therapeutics Deal Termination with Tumim Stone Capital LLC

Allarity Therapeutics terminated its Common Stock Purchase Agreement with Tumim Stone Capital, effective October 28, 2026. The agreement had allowed the company to sell up to $6.0 million of common stock at its discretion, but Allarity elected to cancel the facility to pursue alternative financing arrangements. No early termination penalties were incurred as a result of the cancellation.

Counterparty
Tumim Stone Capital LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.